When Would You Use Single Inhaler Triple Therapy in COPD?

Slides:

Advertisements

Similar presentations

AUGUST Is a blend of dry botanical extracts, mixed in honey and date syrup. Each botanical extract has been authorized and defined by the Israeli.

Advertisements

GOLD 2017 major revision: Summary of key changes

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

COPD – Primary Care Update

Upfront Combination Therapy vs Step-Up Approach for PAH:

Moderate-to-Severe Asthma Management

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

Practical Recommendations for COPD:

COPD by the Guidelines.

Treatment Strategies in Mild to Moderate COPD

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Optimizing Therapy for Osteoarthritis

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

A CASE CHALLENGE IN HFrEF:

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

COPD Management.

Stepping Up Asthma Control for Effective Management

Managing Complex Hypertension: What Every Physician Should Know

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Volume 153, Issue 4, Pages (April 2018)

Volume 153, Issue 4, Pages (April 2018)

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

An Interprofessional Approach to the Patient With Chronic Airway Disease.

Chronic Idiopathic Urticaria

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Combination Inhaled Therapy in COPD: The Impact of Recent Data

PAH Therapy Revisited.

Treating Vasodilatory Shock in the ICU

Patient-Centric Approach to the Management of Spasticity

HCV Protease Inhibitors in Clinical Practice

Efficacy and Safety of Edoxaban in Patients With AF and HF

Precision Medicine Urgency

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Learning Objectives Classification of VTE Goals of VTE Treatment.

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

A Primer on Medication Delivery Systems in COPD Management

Managing Polycythemia Vera in the Community Setting

Aspirin and Cardioprevention in 2018

Preventing Clinical Events in PAH

A Primer on Medication Delivery Systems in COPD Management

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Long-Acting Agents in Severe COPD

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

HCV Protease Inhibitors in Clinical Practice

Personalizing COPD Therapy According to Recent Clinical Trial Evidence

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Communicating With Your Patients About Major Depressive Disorder

Incorporating Prostacyclins Into Practice

Improving Adherence to Antiplatelet Therapy After an ACS Event

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Assessing the Burden of Hyperkalemia

Disease Burden of VTE Phases of VTE Treatment.

Assessing the Burden of Hyperkalemia

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Pathophysiologic Targets of Allergic Asthma

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Merging the Art and Science of Managing nOH in Clinical Practice

Practical Recommendations for COPD:

My PAH Patient.

Targeted Care for COPD.

The Asthma Treatment Gap

PCSK9 Inhibitors and Real-World Evidence

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Agenda. Diagnosis, Assessment, and Treatment of the COPD Patient in Primary Care.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Presentation transcript:

When Would You Use Single Inhaler Triple Therapy in COPD?

Objectives of Treatment

GOLD 2018: Pharmacologic Treatment Recommendations

GOLD 2018: Pharmacologic Treatment Recommendations (cont)

GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

Anti-Inflammatory Therapy in Stable COPD

WISDOM: Exacerbation Risk in Patients With Prior Exacerbations and Elevated Blood Eosinophils

Blood Eosinophils and Prediction of ICS Effects

Anti-Inflammatory Therapy in Stable COPD

Associated Measures

Associated Measures (cont)

Individualized Benefit-Risk Assessment

Triple Inhaled Therapy

GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

Advantages of a Single Inhaler Therapy

LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA in the IMPACT Trial

IMPACT: Incidence of Pneumonia

LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA in the IMPACT Trial

LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE Trial

LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE Trial (cont)

Main Adverse Events in the TRIBUTE Trial

Advantages of a Single Inhaler Therapy

Adherence to Inhaled Therapy and Mortality

GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

Conclusion

Abbreviations

Abbreviations (cont)